[go: up one dir, main page]

AR036250A1 - Una combinacion antineoplasica, un producto que la comprende y el uso de dicha combinacion para la fabricacion de un medicamento para el tratamiento de un neoplasma en un mamifero - Google Patents

Una combinacion antineoplasica, un producto que la comprende y el uso de dicha combinacion para la fabricacion de un medicamento para el tratamiento de un neoplasma en un mamifero

Info

Publication number
AR036250A1
AR036250A1 ARP020102977A ARP020102977A AR036250A1 AR 036250 A1 AR036250 A1 AR 036250A1 AR P020102977 A ARP020102977 A AR P020102977A AR P020102977 A ARP020102977 A AR P020102977A AR 036250 A1 AR036250 A1 AR 036250A1
Authority
AR
Argentina
Prior art keywords
cancer
combination
treatment
product
neoplasm
Prior art date
Application number
ARP020102977A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR036250A1 publication Critical patent/AR036250A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • External Artificial Organs (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Una combinación antineoplásica, que comprende 42-ester de rapamicina con el ácido 3-hidroxi-2-(hidroximetil)-2-metilpropiónico (CCI-779) y [4-(3-cloro-4-fluor-fenilamino)-3-ciano-7-etoxi-quinolin-6-il] amida del ácido 4-dimetilamino-but-2-enoico (EKB-569); un producto que comprende la combinación antedicha, para ser empleado en el tratamiento de uno de los siguientes neoplasmas: cáncer renal, sarcoma de tejido blando, cáncer de mama, tumor neuroendocrino del pulmón, cáncer cervical, cáncer uterino, cáncer de cabeza y cuello, glioma, cáncer de pulmón a célula no pequena, cáncer de próstata, cáncer pancreático, linfoma, melanoma, cáncer de pulmón a célula pequena, cáncer de ovario, cáncer de colon, cáncer de esófago, cáncer gástrico, leucemia, cáncer colonrrectal o cáncer primario desconocido y el uso de dicha combinación para la fabricación de un medicamento para el tratamiento de un neoplasma en un mamífero
ARP020102977A 2001-08-07 2002-08-06 Una combinacion antineoplasica, un producto que la comprende y el uso de dicha combinacion para la fabricacion de un medicamento para el tratamiento de un neoplasma en un mamifero AR036250A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31064601P 2001-08-07 2001-08-07

Publications (1)

Publication Number Publication Date
AR036250A1 true AR036250A1 (es) 2004-08-25

Family

ID=23203475

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020102977A AR036250A1 (es) 2001-08-07 2002-08-06 Una combinacion antineoplasica, un producto que la comprende y el uso de dicha combinacion para la fabricacion de un medicamento para el tratamiento de un neoplasma en un mamifero
ARP050104937A AR051778A2 (es) 2001-08-07 2005-11-25 Derivados del acido dimetilaminocrotonico y procesos para supreparacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP050104937A AR051778A2 (es) 2001-08-07 2005-11-25 Derivados del acido dimetilaminocrotonico y procesos para supreparacion

Country Status (26)

Country Link
US (4) US6617333B2 (es)
EP (2) EP1414438B1 (es)
JP (2) JP2005505549A (es)
KR (1) KR20040029406A (es)
CN (3) CN101279983A (es)
AR (2) AR036250A1 (es)
AT (1) ATE314069T1 (es)
AU (2) AU2002330994B2 (es)
BR (1) BR0211769A (es)
CA (1) CA2455126A1 (es)
CY (1) CY1104983T1 (es)
DE (1) DE60208385T2 (es)
DK (1) DK1414438T3 (es)
EA (2) EA200501251A1 (es)
ES (1) ES2252512T3 (es)
HU (1) HUP0401089A3 (es)
IL (2) IL159859A0 (es)
MX (1) MXPA04001118A (es)
NO (2) NO325503B1 (es)
NZ (3) NZ560845A (es)
PL (1) PL368303A1 (es)
SG (1) SG170612A1 (es)
TW (2) TWI305527B (es)
UA (1) UA77200C2 (es)
WO (1) WO2003020266A1 (es)
ZA (1) ZA200401801B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP1363627A2 (en) 2001-02-19 2003-11-26 Novartis AG Treatment of solid tumours with rapamycin derivatives
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
DE60231868D1 (de) * 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
AU2003243226A1 (en) * 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
WO2004093854A2 (en) * 2003-04-22 2004-11-04 Wyeth Antineoplastic combinations
JP2007501238A (ja) * 2003-08-01 2007-01-25 ワイス・ホールディングズ・コーポレイション 癌の治療および阻害のための上皮増殖因子受容体キナーゼ阻害剤と細胞障害性物質との組み合わせの使用
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
BRPI0418373A (pt) * 2004-01-08 2007-05-22 Wyeth Corp composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado
US7432377B2 (en) * 2004-01-16 2008-10-07 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US8288557B2 (en) * 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
CN101048152A (zh) * 2004-10-28 2007-10-03 惠氏公司 mTOR抑制剂在治疗子宫平滑肌瘤中的应用
BRPI0606839B8 (pt) 2005-02-03 2021-12-14 Massachusetts Gen Hospital Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr)
NZ560840A (en) 2005-03-07 2009-07-31 Robarts Res Inst Use of a combination of myxoma virus and rapamycin for therapeutic treatment
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
TW200716557A (en) * 2005-05-25 2007-05-01 Wyeth Corp Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
CN101180269A (zh) * 2005-05-25 2008-05-14 惠氏公司 制备3-氰基-喹啉的方法和由其制得的中间体
RU2007140957A (ru) * 2005-05-25 2009-06-27 Вайет (Us) Способы синтеза производных 6-алкиламинохинолинов
RU2007143434A (ru) * 2005-06-24 2009-07-27 Вайет (Us) 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний
WO2007005462A1 (en) * 2005-07-01 2007-01-11 Wyeth Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
EP2374480A3 (en) * 2005-08-19 2013-05-01 Endocyte, Inc. Mutli-drug ligand conjugates
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
AU2016259316B2 (en) * 2005-11-04 2018-09-06 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
AU2013204788B2 (en) * 2005-11-04 2016-12-08 Wyeth Llc Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
RU2451524C2 (ru) * 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
ES2481671T3 (es) 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008121467A2 (en) * 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
NZ599239A (en) * 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP2176293B1 (en) * 2007-06-25 2019-04-03 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2008316835B2 (en) 2007-10-25 2015-07-16 Endocyte, Inc. Tubulysins and processes for preparing
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
SG191676A1 (en) 2008-06-17 2013-07-31 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
CA2745238A1 (en) * 2008-12-02 2010-06-10 Biocompatibles Uk Limited Pancreatic tumour treatment
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
ES2622881T3 (es) 2010-09-29 2017-07-07 Intervet International B.V. Compuestos de N-heteroarilo
WO2012041872A1 (en) 2010-09-29 2012-04-05 Intervet International B.V. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
IN2015DN04147A (es) 2012-10-16 2015-10-16 Endocyte Inc
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
US9242965B2 (en) * 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
SG11201805286RA (en) * 2015-12-24 2018-07-30 Kyowa Hakko Kirin Co Ltd α,β-UNSATURATED AMIDE COMPOUND

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU415255A1 (ru) * 1972-03-20 1974-02-15 Т. А. Асонова, А. Я. Берлин, А. Б. Зезин, Е. Ф. Разводовский СПОСОБ ПОЛУЧЕНИЯ р-БЕТАИ1ЮВВПТВci)iia aiisn^pii
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4194050A (en) 1976-04-30 1980-03-18 Sumitomo Chemical Company, Limited Process for producing an enamide
US4195021A (en) 1977-10-26 1980-03-25 Eli Lilly And Company 1,3-Disubstituted 2-azetidinone antibitotics
US4193983A (en) 1978-05-16 1980-03-18 Syva Company Labeled liposome particle compositions and immunoassays therewith
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5066493A (en) 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
BE897134A (fr) 1983-06-24 1983-12-27 Solvay Dienes polysubstitues
US4478959A (en) 1983-09-29 1984-10-23 Air Products And Chemicals, Inc. Amino and amido divalent metal carboxylates useful as catalysts for polyurethane formulations
DE3347659A1 (de) 1983-12-31 1985-07-11 Bayer Ag, 5090 Leverkusen Neue lackloesungen auf der basis von hydantoingruppen enthaltenden polymeren
US4664825A (en) 1984-10-25 1987-05-12 The Lubrizol Corporation Sulfurized compositions and lubricants containing them
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
AU634871B2 (en) 1990-03-20 1993-03-04 Banyu Pharmaceutical Co., Ltd. Substituted amine derivatives having anti-hyperlipemia activity
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ATE135583T1 (de) 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
CN1069492A (zh) * 1991-08-21 1993-03-03 山之内制药株式会社 4-酰胺基咪唑衍生物
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5352783A (en) 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5547948A (en) 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
CA2369303A1 (en) * 1999-04-14 2000-10-19 Arthur B. Pardee Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
WO2002013802A2 (en) * 2000-08-11 2002-02-21 Wyeth Method of treating estrogen receptor positive carcinoma
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.

Also Published As

Publication number Publication date
AU2002330994B2 (en) 2007-10-04
EP1671943A1 (en) 2006-06-21
EA011098B1 (ru) 2008-12-30
CN101279983A (zh) 2008-10-08
NZ560845A (en) 2008-09-26
CN1538842A (zh) 2004-10-20
TWI300351B (en) 2008-09-01
NO325503B1 (no) 2008-05-26
EP1414438A1 (en) 2004-05-06
USRE41084E1 (en) 2010-01-19
US6617333B2 (en) 2003-09-09
JP2005505549A (ja) 2005-02-24
DE60208385D1 (de) 2006-02-02
CN100415753C (zh) 2008-09-03
US20030050222A1 (en) 2003-03-13
EP1414438B1 (en) 2005-12-28
DK1414438T3 (da) 2006-03-27
DE60208385T2 (de) 2006-08-03
IL159859A (en) 2009-12-24
USRE41253E1 (en) 2010-04-20
MXPA04001118A (es) 2004-05-20
ATE314069T1 (de) 2006-01-15
NO20040558L (no) 2004-02-06
NO20073801L (no) 2004-02-06
BR0211769A (pt) 2004-07-27
HUP0401089A2 (hu) 2004-09-28
TW200626526A (en) 2006-08-01
HK1061204A1 (en) 2004-09-10
KR20040029406A (ko) 2004-04-06
CY1104983T1 (el) 2010-03-03
CN1326523C (zh) 2007-07-18
CA2455126A1 (en) 2003-03-13
TWI305527B (en) 2009-01-21
ES2252512T3 (es) 2006-05-16
ZA200401801B (en) 2005-06-06
AU2006233165B2 (en) 2009-12-24
JP2010155845A (ja) 2010-07-15
AU2006233165A1 (en) 2006-11-09
NZ542272A (en) 2007-12-21
EA200501251A1 (ru) 2008-12-30
HUP0401089A3 (en) 2007-12-28
WO2003020266A1 (en) 2003-03-13
SG170612A1 (en) 2011-05-30
EA200400284A1 (ru) 2004-06-24
USRE40418E1 (en) 2008-07-01
EA006226B1 (ru) 2005-10-27
PL368303A1 (en) 2005-03-21
NZ530847A (en) 2006-02-24
CN1803806A (zh) 2006-07-19
IL159859A0 (en) 2004-06-20
AR051778A2 (es) 2007-02-07
UA77200C2 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
AR036250A1 (es) Una combinacion antineoplasica, un producto que la comprende y el uso de dicha combinacion para la fabricacion de un medicamento para el tratamiento de un neoplasma en un mamifero
AR035450A1 (es) Combinaciones antineoplasicas, el uso de dichas combinaciones para la preparacion de un medicamento, un producto que comprende dicha combinacion
MX2019010879A (es) Tratamiento de cancer.
ATE302775T1 (de) Carbolinderivate
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ATE346067T1 (de) Carbolinderivate
ES2123996T3 (es) Analogos de 7-etertaxol, uso antineoplasico y composiciones farmaceuticas que los contienen.
EA200200876A1 (ru) Алкилированные производные имидазопиридина
PH12022553333A1 (en) Markers for use in methods for treating cancers with antibody drug conjugates (adc)
DE60002855D1 (de) Haloalkoxy-imidazonaphthyridine
NZ524936A (en) Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor
AR034071A1 (es) Combinaciones antineoplasicas
MX2023007918A (es) Uso de un inhibidor de kras g12c en el tratamiento de canceres.
WO2005105753A3 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
DE60127131D1 (de) Tricyclische imidazopyridine
ATE259813T1 (de) Triazolopyrimidinderivate
HN2002000377A (es) Peptidos para el tratamiento del cancer asociado al virus papiloma humano (v p h ) y de otros tumores epiteliales
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
DE60112966D1 (de) Trizyklische indolderivate mit antiangiogenischer wirkung
MXPA02012163A (es) Composiciones farmaceuticas que comprenden derivados de acriloil-distamicina e inhibidores de topoisomerasa 1 y 11.
BR0014687A (pt) Compostos de taxano pentacìclico
YU59403A (sh) Androgeni 7-supstituisani 11-halogenovani steroidi
DE60215918D1 (de) Azofarbstoffe
AU2001292698A1 (en) Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction

Legal Events

Date Code Title Description
FB Suspension of granting procedure